The Cleveland Clinic Lou Ruvo Center for Brain Health in Las Vegas and the Cleveland Clinic in Ohio are now welcoming clinical trial volunteers for testing of an experimental drug to help determine if it can slow down the progression of symptoms in early Alzheimer’s Disease.
The worldwide clinical trial, known as EMERGE, seeks men and women between 50 and 85 who suffer from Alzheimer’s and experience mild cognitive impairment with common symptoms such as memory loss.
“We are very excited to add the EMERGE study to the extensive list of clinical trials here in Las Vegas and in Cleveland,” said Dr. Kate Zhong, Senior Director of Clinical Research and Development for the Cleveland Clinic Lou Ruvo Center for Brain Health. “With every trial conducted, we learn more about the diseases we treat here and become one step closer to our ultimate goal of finding a cure.”
Study participants will receive monthly injections during the course of the 78-week trial. The severity of dementia and changes in functional and cognitive impairment in participants will be measured and compared to evaluate the drug’s ability in slowing the progression of the disease. “This is the most promising drug we have seen for Alzheimer’s Disease.
We have never seen a drug before that both reduces the toxins in the brain and stabilizes decline,” said Dr. Jeffrey Cummings, Director of the Lou Ruvo Center for Brain Health.
The study has progressed to a Phase 3 trial, where treatment is provided to large groups of people to confirm its effectiveness, monitor side effects, and collect information to ensure patient safety.